Ipsen (I7G) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Ipsen DE:I7G is currently developing the following drugs: Ipn10200, Elafibranor, Ipn01203, Ipn60300, Palovarotene, Ipn01195, Ipn10200, Ipn10200 Dose A, Ipn10200 Dose B, Cabozantinib, Best Supportive Care, Ipn01194, Tazverik, Botulinum Toxin Type A, Elafibranor 80 Mg, Elafibranor 120 Mg, Triptorelin Pamoate Salt, Triptorelin Embonate 22.5 Mg, 5-Fluorouracil, Folinic Acid, Irinotecan Liposome Injection, Ipn60130, Triptorelin Pamoate, Abobont-A, Onabont-A, Lanreotide Autogel, Ipn10200, Dysport, Palovarotene, Vehicle, Triptorelin Pamoate 15Mg, Ipn59011, Azzalure, 111In-Ipn01087 Low Dose, 111In-Ipn01087 High Dose, Elafibranor 80Mg, Leucovorin, Oxaliplatin, Gemcitabine, Nab-Paclitaxel, 5Fluorouracil, Irinotecan Liposomal Injection, Cabozantinib, Cabometyx, Pembrolizumab, Paclitaxel, Ipn60090, Ipn60090 Single Administration, Satoreotide Trizoxetan, Satoreotide Tetraxetan. These drug candidates are in various stages of clinical development as the company works toward FDA approval.